Research · Sep 3, 2026
[ELAN] Elanco Animal Health Thesis 2026: Companion Animal Innovation Drives Farm Animal Cycle Recovery
Elanco Animal Health Inc. (NYSE: ELAN) FY2025 revenue ~$4.45-4.65B (+1-5%) with adj. EPS ~$0.92-1.10 reflecting continued post-2024 ~$2.30-2.45B aggregate Pet Health revenue (~52% aggregate revenue mix; selected primary Companion Animal innovation + selected various Credelio Quattro + Zenrelia + Bovaer launches) + selected continued post-2024 ~$2.10-2.25B aggregate Farm Animal revenue (~48% aggregate revenue mix; selected primary Cattle + Poultry + Aqua + Swine production animal health) under continued President + CEO Jeff Simmons since 2018 (~7-year tenure as Elanco CEO; selected post-2018 Eli Lilly spinoff). One of the largest US + global Companion Animal + Farm Animal health companies. Founded 1954 as Elanco division of Eli Lilly + Co. in Greenfield Indiana (~71-year heritage); selected post-September 2018 NYSE IPO following ~$5B+ Eli Lilly spinoff; selected post-July 2020 ~$7.6B+ Bayer Animal Health acquisition; selected post-July 2024 Credelio Quattro FDA approval; selected post-September 2024 Zenrelia FDA approval; selected post-November 2024 Bovaer US launch. Headquartered in Greenfield Indiana; ~9,000+ employees globally with ~$4.45-4.65B revenue. Two primary business segments: Pet Health (~52% ~$2.30-2.45B), Farm Animal (~48% ~$2.10-2.25B). Geographic mix: US ~50%+ + International ~50%. Companion animal innovation cycle: ~$2.30-2.45B Pet Health revenue; selected post-July 2024 Credelio Quattro (broad-spectrum parasiticide) FDA approval; selected post-September 2024 Zenrelia (atopic dermatitis JAK inhibitor) FDA approval; selected post-November 2024 Bovaer (methane reducer) US launch; selected projected ~$300-500M aggregate cumulative innovation portfolio peak revenue. Farm animal cycle recovery + post-2020 Bayer Animal Health integration: ~$2.10-2.25B Farm Animal revenue; selected continued post-2020 ~$7.6B+ Bayer Animal Health acquisition integration; selected various ~3-5% aggregate organic Farm Animal growth. President + CEO Jeff Simmons since 2018 (~7-year tenure); CFO Todd Young. Capital return: ~$0 dividend (no dividend track post-2018 NYSE IPO); minimal opportunistic buybacks; ~$0.4-0.5B aggregate cash + investments balance; net leverage ~5.0-5.5x net debt-to-adj. EBITDA; ~$0.5-0.7B aggregate annual debt paydown; B1/BB credit rating; selected projected post-2027 investment-grade upgrade. FY2026 thesis: Companion animal innovation cycle (Credelio Quattro + Zenrelia + Bovaer) + Farm animal cycle recovery + selected post-2020 Bayer Animal Health integration + ~$0.5-0.7B aggregate annual debt paydown + selected projected post-2027 investment-grade upgrade. Risks: Zoetis + Boehringer Ingelheim + Merck Animal Health (MSD) + Virbac competition, Credelio Quattro + Zenrelia + Bovaer launch slower-than-expected, Farm Animal cycle, Bayer integration considerations, sustained ~5.0-5.5x net leverage.